Prevalence of herbal medicine consumption and regulatory compliance in some selected districts of the Bono region, Ghana.

Abstract

Background: Though herbal medicine remains a vital component of healthcare in the Bono region of Ghana, knowledge of its prevalence, factors influencing the choice of herbal remedies, and compliance with quality control standards among the herbal medicine practitioners in the region is lacking. This situation adversely affects health outcomes, regulatory standards, and public trust in herbal medicines in the region.

Aim: This study aimed at assessing the prevalence of herbal medicine use, factors that dictate the choice of herbal medicine, and adherence to quality control practices in the Bono region of Ghana.

Method: A cross-sectional study with 504 recruited herbal medicine consumers and 98 practitioners, selected across four districts of the Bono region, was used. Paper-pencil questionnaires were used to obtain respondents' sociodemographic data. The chi-square (χ2) test was used to assess associated factors, while logistic regression analysis was used to determine the factors associated with herbal medicine use.

Results: It was revealed that 92.7% of the respondents had used herbal medicine within the past 24 months. Old age (P < 0.001), farming (P < 0.001), self-employment (P < 0.004), unemployment (P < 0.049), and no formal education (P < 0.044) were associated with herbal medicine usage. Of the 98 practitioners, 44.9% had active FDA licenses, and 59.2% had undergone formal training in quality control practices at recognized institutions. Of the 73 herbal products identified, 46.5% had no FDA registration certification, 42.5% had no information on unwanted effects and contraindications, and 26% had no expiry dates.

Conclusion: The study highlighted a widespread use of herbal medicine and a significant regulatory compliance gap in the Bono region. As herbal medicine remains an essential remedy in this area, commitments from the government, regulatory bodies, practitioners, and the general public are required to improve regulatory adherence to safeguard public health.

Clinical trial number: Not applicable.